Cisen Pharmaceutical (603367) Fundamentals 2026 — P/E 15.8x, Revenue Analysis | SniperIQ
Cisen Pharmaceutical (603367) is a CN-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ¥6.5B, trading at ¥14.30 on the SHH. This SniperIQ fundamentals page covers Cisen Pharmaceutical's valuation (P/E 15.8x, P/B 1.0x), profitability (net margin 12.1%), revenue (¥3.4B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Cisen Pharmaceutical's market cap?
Cisen Pharmaceutical (603367) has a market capitalization of approximately ¥6.5B, trading at ¥14.30 on the SHH. Market cap moves with the live share price.
What is Cisen Pharmaceutical's P/E ratio?
Cisen Pharmaceutical's trailing twelve-month P/E ratio is 15.8x, with a price-to-book (P/B) of 1.0x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Cisen Pharmaceutical?
Cisen Pharmaceutical runs a net profit margin of 12.1%, a gross margin of 47.4%, and an operating margin of 11.9%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Cisen Pharmaceutical generate?
Cisen Pharmaceutical reported revenue of ¥3.4B for fiscal year 2025, with net income of ¥421M and earnings per share (EPS) of 0.93. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Cisen Pharmaceutical pay a dividend?
Cisen Pharmaceutical offers a trailing dividend yield of about 2.4%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Cisen Pharmaceutical financially healthy?
Cisen Pharmaceutical carries a debt-to-equity ratio of 0.04x and a current ratio of 4.65x, with a market beta of 0.15. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Cisen Pharmaceutical a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Cisen Pharmaceutical (603367) the key facts are: market cap ¥6.5B, P/E 15.8x, revenue ¥3.4B, 52-week range 12.13-35.2. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Cisen Pharmaceutical's full fundamentals live
Get Cisen Pharmaceutical's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.